Q2 2026 Liquidia Corp Earnings Call Transcript
Key Points
- Liquidia Corp (LQDA) reported strong Q2 2026 financial results with YUTREPIA net product sales of $170.4 million, up 31% quarter-over-quarter, and net income of approximately $74.7 million.
- The company has achieved four consecutive quarters of increasing profitability and generated significant cash flow, ending the quarter with $284.2 million in cash, up $61.4 million from Q1.
- YUTREPIA has seen robust commercial adoption with over 5,000 patients started on therapy and 1,100 physicians prescribing, with 30% of those physicians having prescribed to five or more patients.
- The company's pipeline is advancing with 10 clinical studies underway or planned, including the Phase 3 Re-Spire trial for L606, which has shown promising tolerability and dose attainment data.
- Liquidia Corp (LQDA) is confident in its growth trajectory, projecting more than $1 billion in net revenue in 2027, driven by market expansion and increasing share of the inhaled prostacyclin market.
- The company's ASCENT study demonstrated progressive improvements in six-minute walk distance with higher doses of YUTREPIA, supporting the tolerability-dose-efficacy paradigm.
- The company faces ongoing legal uncertainty regarding the '327 patent trial, with no visibility into the judge's decision timeline, which could result in royalties or other adjunctive relief if the ruling goes against them.
- R&D expenses are expected to double in the second half of 2026 and increase again in 2027, which could pressure near-term profitability despite revenue growth.
- YUTREPIA requires a 4 times daily dosing regimen, which may be a burden for patients compared to potentially more convenient alternatives like L606.
- The company acknowledges that patient discontinuation rates could be affected by comorbidities in the severely ill patient population, and long-term adherence data is still being collected.
- Growth in the community setting is described as a 'slow burn,' with significant work needed to penetrate and identify the estimated 60,000 patients in the community, which may limit near-term acceleration in patient adds.
- The company faces competition from other inhaled treprostinil products, and cross-study comparisons with TPIP suggest potential differences in dose attainment and efficacy that could impact market positioning.
Good morning, and welcome to the Liquidia Corporation second-quarter 2026 financial results and corporate update conference call. My name is Daniel, and I will be your operator today. (Operator Instructions) Please note that today's call is being recorded.
I'll now turn the call over to Jason Adair, Liquidia's Chief Business Officer.
Thank you, and good morning, everyone. It's my pleasure to welcome you to our second-quarter 2026 financial results and corporate update call. Joining me today are Dr. Roger Jeffs, Chief Executive Officer; Michael Kaseta, Chief Operating Officer and Chief Financial Officer; Dr. Rajeev Saggar, Chief Medical Officer; Scott Moomaw, Chief Commercial Officer; and Rusty Schundler, General Counsel.
Before we begin, please note that today's discussion will include forward-looking statements, including statements regarding future results, product performance and ongoing clinical or commercial activities. These statements are subject to risks and uncertainties that may
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
